BioMarin to Present at the Citi Biotech Day
Posted on: Tuesday, 2 September 2008, 09:00 CDT
NOVATO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 3rd Annual Citi Biotech Day in New York City on Monday, September 8, 2008 at 10:30 a.m. ET.
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.bmrn.com/. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.bmrn.com/. Information on BioMarin's website is not incorporated by reference into this press release.
BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-6594
BioMarin Pharmaceutical Inc.
CONTACT: Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg,+1-415-506-6594, both of BioMarin Pharmaceutical Inc.
Web site: http://www.bmrn.com/
Source: PRNewswire-FirstCall
Related Articles
- Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes
- Metabasis Announces Preliminary Safety and Efficacy Results From an Ongoing Phase 1b Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
- Metabasis Announces Orphan Drug Designation Granted to MB07133, Its Product Candidate for the Treatment of Primary Liver Cancer
- Collegium Pharmaceutical Provides Update on Development of Its Nasal Inhaled Steroid for Allergic Rhinitis
- ProEthic Pharmaceuticals Announces Positive Phase III Clinical Trial Results for Fast-Acting Migraine Product Candidate
- BioLineRx In-Licenses BL-3010 From Gevys Pharmaceuticals for the Treatment of Pain and Plans to Initiate Phase I/II Trial
- Pro-Pharmaceuticals Presents Phase II/III Clinical Trials at the Central European Society for Anti-Cancer Drug Research Conference
- Manhattan Pharmaceuticals' Topical Psoriasis Treatment in Phase IIa Trial
- Galderma USA Announces New Product for the Topical Treatment of Rosacea
- Somaxon Pharmaceuticals, Inc. Initiates Phase III Clinical Trials of SILENOR in Patients With Insomnia
 |
 |
User Comments (0)
RSS Feeds